What is RISA?
Founded in 2024 and headquartered in Palo Alto, California, RISA Labs operates at the intersection of artificial intelligence and healthcare technology. The company specializes in automating the critical process of oncology prior authorization, employing advanced AI-driven multi-agent systems. RISA's platform is designed for seamless integration with major Electronic Health Record (EHR) systems. It leverages generative AI, robotic process automation, and a robust rules engine to streamline administrative workflows. By addressing treatment delays and enhancing compliance, RISA aims to significantly improve patient outcomes and operational efficiency for healthcare providers navigating the intricacies of cancer care.
How much funding has RISA raised?
RISA has raised a total of $14.6M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$11.1M
Angel/Seed (2025): $3.5M with participation from Binny Bansal, General Catalyst, and Oncology Ventures
Series A (2026): $11.1M led by Optum Ventures
Key Investors in RISA
Binny Bansal
Undisclosed investor participating in the funding round.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages. The firm deploys capital strategically to back entrepreneurs and management teams pursuing ambitious visions that reshape their respective industries.
Oncology Ventures
Oncology Ventures is dedicated to investing in healthcare data companies that address significant challenges in cancer care, focusing on early detection, patient navigation, and AI-powered treatment optimization. The company aims to improve the fragmented and costly U.S. oncology system by funding technologies that enhance evidence-based care.
What's next for RISA?
The substantial enterprise-level funding and recent strategic investment position RISA for accelerated expansion and market penetration. With a clear focus on automating oncology prior authorization, the company is poised to address a critical bottleneck in cancer care delivery. Future developments are likely to involve further enhancement of its AI capabilities, broader integration with healthcare systems, and strategic partnerships to scale its impact. This capital infusion will support RISA's mission to reduce administrative burdens, expedite patient access to treatment, and ultimately improve the overall quality of oncology care.
See full RISA company page
